AI Terminal
Flerie AB
Net Asset Value • Mar 5, 2025
6601_rns_2025-03-05_9fa2b1af-eabc-48f3-9dc0-ed750349feaf.pdf
Net Asset Value
Open in ViewerOpens in native device viewer
NET ASSET VALUE – 28 February 2025
On the 28 February 2025 Flerie AB's Net Asset Value (NAV) was SEK 4,063 million and NAV per share was SEK 52.05.
| Share of portfolio | Fair value | Part of NAV per share | Share of | |
|---|---|---|---|---|
| Allocation of NAV | company | (MSEK) | (SEK) | NAV |
| Product Development | ||||
| Prokarium | 42% | 476 | 6.09 | 11.7% |
| Xspray Pharma | 18% | 209 | 2.68 | 5.2% |
| Empros Pharma | 79% | 204 | 2.62 | 5.0% |
| KAHR Medical | 31% | 203 | 2.60 | 5.0% |
| Lipum | 57% | 196 | 2.51 | 4.8% |
| Atrogi | 37% | 176 | 2.25 | 4.3% |
| Xintela | 61% | 162 | 2.08 | 4.0% |
| Microbiotica | 10% | 135 | 1.73 | 3.3% |
| Geneos Therapeutics | 12% | 103 | 1.32 | 2.5% |
| Mendus | 24% | 95 | 1.21 | 2.3% |
| AnaCardio | 14% | 69 | 0.89 | 1.7% |
| Toleranzia | 66% | 67 | 0.86 | 1.6% |
| EpiEndo Pharmaceuticals | 9% | 55 | 0.71 | 1.4% |
| Synerkine Pharma | 43% | 55 | 0.71 | 1.4% |
| Vitara Biomedical | 10% | 54 | 0.69 | 1.3% |
| Egetis Therapeutics | 2% | 29 | 0.37 | 0.7% |
| Buzzard Pharmaceuticals | 14% | 29 | 0.37 | 0.7% |
| Sixera Pharma | 24% | 27 | 0.35 | 0.7% |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
| Amarna Therapeutics | 58% | 11 | 0.15 | 0.3% |
| Strike Pharma | 16% | 9 | 0.11 | 0.2% |
| Total | 2,383 | 30.53 | 58.6% | |
| Commercial Growth | ||||
| NorthX Biologics | 92% | 189 | 2.42 | 4.7% |
| Symcel | 31% | 174 | 2.23 | 4.3% |
| Chromafora | 31% | 73 | 0.93 | 1.8% |
| Nanologica | 43% | 72 | 0.92 | 1.8% |
| A3P Biomedical | 8% | 46 | 0.59 | 1.1% |
| Frontier Biosolutions | 2% | 19 | 0.24 | 0.5% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Provell Pharmaceuticals* | 72% | 0 | 0.00 | 0.0% |
| Total | 589 | 7.54 | 14.5% | |
| Limited Partnerships, total | 85 | 1.08 | 2.1% | |
| Net asset value | 4,063 | 52.05 | 100.0% |
|---|---|---|---|
| Other assets and liabilities | 761 | 9.75 | 18.7% |
| Assets related to Portfolio companies |
245 | 3.14 | 6.0% |
* indirect shares in Provell Pharmaceuticals
For more information:
Ted Fjällman, CEO Email: [email protected]
Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com